- AuthorisedTherapeutic use (Phase IV)
Prospective evaluation of potential effects of repeated gadolinium-based contrast agent (GBCA) administrations of the same GBCA on motor and cognitive functions in neurologically normal adults in comparison to a non-GBCA exposed control group—ODYSSEY
This study, called ODYSSEY, checks if repeated use of certain MRI dyes over five years affects your movement or thinking. It compares people who get these dyes to those who don't. We want to understand if there are any long-term effects.
Italy · Germany · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
PLAQUE AND BRAIN INFLAMMATION IN SYMPTOMATIC CAROTID STENOSIS: ROLE OF THE FICOLIN-2 STATEMENT
This study looks at how a protein called ficolin-2 in the blood might be linked to brain inflammation and fatty deposits (plaque) in arteries that lead to the brain. Researchers want to understand these links better, especially in people who have had a stroke or mini-stroke.
For: stroke or transient ischemic attackFrance - Ongoing, recruitingTherapeutic confirmatory (Phase III)
(21197) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of any body region (except CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs)
This study compares a new MRI dye, gadoquatrane, with existing dyes. It aims to see if the new dye helps doctors get clearer images of body parts (but not the brain or spine) and if it's safe to use.
For: Contrast enhancement in magnetic resonance imaging for assessment of non-central nervous system pathologyCzechia · Sweden · Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
(21181) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of the central nervous system (CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs)
This study is testing a new, lower-dose contrast dye called gadoquatrane for MRI brain scans. It wants to see if it's as good and safe as current higher-dose dyes at showing problems in the brain and spinal cord, like tumours or inflammation.
For: Contrast enhancement in magnetic resonance imaging for assessment of central nervous system pathologySweden · France · Bulgaria - Ongoing, recruitingTherapeutic exploratory (Phase II)
An Adaptive Phase 2a/2b, Randomized, Double-Blind, Parallel-Group Study to Investigate the Safety and Efficacy of LY3541860 Compared to Placebo in Slowing the Occurrence of New T1 Gadolinium-Enhancing Lesions in Adult Participants with Relapsing Multiple Sclerosis
This study is looking into a new medicine, LY3541860, for people with relapsing multiple sclerosis (RMS). Researchers want to see if it can reduce the number of new spots on the brain (lesions) compared to a dummy treatment (placebo).
For: Relapsing Multiple SclerosisItaly · Lithuania · Germany - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
[18F]-Fludarabine PET/MR Imaging for the Assessment of Newly-diagnosed Primary Central Nervous System (CNS) Lymphoma : a Pilot PET-MRI Study
This study looks at a new way to scan newly diagnosed brain lymphoma using a special tracer ([18F]-Fludarabine) with PET-MRI. It aims to see how well this new scan can highlight the cancer compared to healthy brain tissue.
For: Patients with newly diagnosed primary central nervous system lymphoma naïve to surgery · radiotherapy or chemotherapyFrance